We call this CEBPB-driven 33-gene set as mitochondriaobesity/neurodegeneration (Mon)-gene-signature (Figure 3D), which at least in Alzheimer’s disease have a connection to γ-Secretase as inhibitors against this enzyme are aimed for Alzheimer’s disease therapy44. This evidence concerns the gene CEBPB and early-onset autosomal dominant Alzheimer disease.